Table 3.

The list of current COVID-19 POC test producing by different companies.

Companies	Product	Time	Method	Approved Status
Abbott ID	ID now TM COVID-19	5 min	Molecular POC test	FDA, EUA
BioMedomics	COVID-19 IgM/IgG Rapid Test	10–15 min	Lateral flow immunoassays (LFA)	FDA
Affinity Health Partners	COVID-19 test	10 min	Immunoassay	FDA
Chembio (Medford, NY, USA)	DPP COVID-19 serological POC test	15 min	Immunoassay	FDA
Mesa Biotech Inc.	Accula SARS-CoV-2 test	30 min	PCR technology	FDA
Cepheid (Sunnyvale, CA, USA)	GeneXpert® Systems	45 min	Real-time RT-PCR	FDA
MiCo BioMed	–	1 h	LabChip-based real-time PCR microfluidic lab-on-a-chip technology	Seeking FDA approval
Fluxergy LLC	Fluxergy Analyzer system	1 h	Polymerase chain reaction and microfluidics technology	Seeking FDA approval

The first FDA-approved POC system was developed by Cepheid (Cepheid GeneXpert® Systems) for the rapid molecular detection of SARS-CoV-2 which could provide results within 45 min and is based on real-time RT-PCR. It is used for qualitative detection of SARS-CoV-2 nucleic acids in a nasopharyngeal swab or nasal wash from individuals suspected of being infected with COVID-19. The system employs disposable cartridges containing the RT-PCR reagents and acting as a platform for the RT-PCR process. The risk of contamination between samples is reduced due to its use of self-contained cartridges. The test costs between $10-$20 per sample (Vashist, 2020; Soon et al., 2013).